Login to Your Account

Tokyo's Daiichi Sankyo aiming to innovate with help from UCSF

By Cornelia Zou
Staff Writer

Wednesday, April 16, 2014

HONG KONG – Daiichi Sankyo Co. Ltd., the second largest pharmaceutical in Japan, has partnered with the University of California, San Francisco (UCSF), in a collaborative drug discovery program to develop therapeutics and diagnostics to treat degenerative diseases such as Alzheimer's disease, Parkinson's disease, Creutzfeldt-Jakob disease and frontotemporal dementias (FTD)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription